Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F; CONVERT Study Team. Faivre-Finn C, et al. Among authors: cardenal f. Lancet Oncol. 2017 Aug;18(8):1116-1125. doi: 10.1016/S1470-2045(17)30318-2. Epub 2017 Jun 20. Lancet Oncol. 2017. PMID: 28642008 Free PMC article. Clinical Trial.
Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.
Faivre-Finn C, Falk S, Ashcroft L, Bewley M, Lorigan P, Wilson E, Groom N, Snee M, Fournel P, Cardenal F, Bezjak A, Blackhall F. Faivre-Finn C, et al. Among authors: cardenal f. BMJ Open. 2016 Jan 20;6(1):e009849. doi: 10.1136/bmjopen-2015-009849. BMJ Open. 2016. PMID: 26792218 Free PMC article. Clinical Trial.
A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer.
Senan S, Cardenal F, Vansteenkiste J, Stigt J, Akyol F, De Neve W, Bakker J, Dupont JM, Scagliotti GV, Ricardi U, van Meerbeeck JP. Senan S, et al. Among authors: cardenal f. Ann Oncol. 2011 Mar;22(3):553-558. doi: 10.1093/annonc/mdq388. Epub 2010 Aug 9. Ann Oncol. 2011. PMID: 20696676 Free article. Clinical Trial.
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer.
Manegold C, Vansteenkiste J, Cardenal F, Schuette W, Woll PJ, Ulsperger E, Kerber A, Eckmayr J, von Pawel J. Manegold C, et al. Among authors: cardenal f. Invest New Drugs. 2013 Feb;31(1):175-82. doi: 10.1007/s10637-012-9842-6. Epub 2012 Jul 3. Invest New Drugs. 2013. PMID: 22752690 Free PMC article. Clinical Trial.
Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer.
Cardenal F, Arnaiz MD, Morán T, Jové J, Nadal E, Porta R, Solé JM, Brao I, Palmero R, Fuentes R, Núñez I, Caveda E, Cassinello A. Cardenal F, et al. Lung Cancer. 2011 Oct;74(1):69-74. doi: 10.1016/j.lungcan.2011.01.021. Epub 2011 Feb 24. Lung Cancer. 2011. PMID: 21353323 Clinical Trial.
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.
Cardenal F, López-Cabrerizo MP, Antón A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, García M, Lianes P, Montalar J, Vadell C, González-Larriba JL, Nguyen B, Artal A, Rosell R. Cardenal F, et al. J Clin Oncol. 1999 Jan;17(1):12-8. doi: 10.1200/JCO.1999.17.1.12. J Clin Oncol. 1999. PMID: 10458212 Clinical Trial.
A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.
Zatloukal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, Cisar L, Soria JC, Domine M, Thomas M. Zatloukal P, et al. Among authors: cardenal f. Ann Oncol. 2010 Sep;21(9):1810-1816. doi: 10.1093/annonc/mdq036. Epub 2010 Mar 15. Ann Oncol. 2010. PMID: 20231298 Free article. Clinical Trial.
Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Bergamino M, Rullan AJ, Saigí M, Peiró I, Montanya E, Palmero R, Ruffinelli JC, Navarro A, Arnaiz MD, Brao I, Aso S, Padrones S, Cardenal F, Nadal E. Bergamino M, et al. Among authors: cardenal f. BMC Cancer. 2019 Feb 21;19(1):165. doi: 10.1186/s12885-019-5370-5. BMC Cancer. 2019. PMID: 30791870 Free PMC article.
Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.
Garrido P, González-Larriba JL, Insa A, Provencio M, Torres A, Isla D, Sanchez JM, Cardenal F, Domine M, Barcelo JR, Tarrazona V, Varela A, Aguilo R, Astudillo J, Muguruza I, Artal A, Hernando-Trancho F, Massuti B, Sanchez-Ronco M, Rosell R. Garrido P, et al. Among authors: cardenal f. J Clin Oncol. 2007 Oct 20;25(30):4736-42. doi: 10.1200/JCO.2007.12.0014. J Clin Oncol. 2007. PMID: 17947721 Clinical Trial.
69 results